PROPEL: A phase 1/2 trial of NKTR-214 (CD122-biased agonist) combined with anti-PD-1 (pembrolizumab) or anti-PD-L1 (atezolizumab) in patients (pts) with advanced solid tumors.
Daniel A. Vaena(West Cancer Center), James K. Schwarz(University of Nebraska Medical Center), Ahsan Rizwan(Nektar Therapeutics (United States)), Ute Hoch(University of Arizona), Michael J. Imperiale(University of Michigan), Marc Matrana(Ochsner Medical Center), Nicholas J. Vogelzang(Comprehensive Cancer Centers of Nevada), Sunny Xie(Nektar Therapeutics (United States)), Matthew J. Riese(Medical College of Wisconsin), Mary Tagliaferri(Nektar Therapeutics (United States)), Jorge Chaves(Northwest Medical Specialties), Daniel C. Cho(NYU Langone Health), Afshin Eli Gabayan(Beverly Hills Cancer Center), Sandra Aung(Nektar Therapeutics (United States)), Jonathan Zalevsky(Nektar Therapeutics (United States))
Cited by 3
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
|Journal of Clinical Oncology|2003|3.1k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k